Publication Details

Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology Network.

Kahl BS, Longo WL, Eickhoff JC, Zehnder J, Jones C, Blank J, McFarland T, Bottner W, Rezazedeh H, Werndli J, Bailey HH. Ann Oncol. 2006; 17 (9): 1418-23

There is no standard first line treatment for mantle cell lymphoma.

PubMedID: 16766582